Kathleen Goin, chief operating officer of Palvella Therapeutics, INC. (NASDAQ:PVLA), executed stock sales totaling $507,610 on March 18, 2026, according to a filed Form 4 with the Securities and Exchange Commission.
The disposal comprised 4,302 shares of common stock, sold at prices ranging from $117.5632 to $119.0817 per share. The filing also shows that Ms. Goin exercised stock options to acquire 4,302 shares of Palvella common stock at exercise prices of $7.14 and $9.08, representing an aggregate exercise value of $34,883.
The transactions were made under a pre-established Rule 10b5-1 trading plan that the company says was adopted on August 19, 2025. The sale occurred amid recent share volatility - the stock has retreated 6.7% over the prior week - though the shares remain up roughly 315% on a year-over-year basis.
Corporate and commercial developments
Palvella has been active on multiple corporate fronts in recent weeks. The company completed a public offering that generated $230 million in gross proceeds through the sale of 1,840,000 shares of common stock at $125.00 apiece. That offering included an underwriter option that was exercised to purchase an additional 240,000 shares.
Separately, the European Patent Office issued European Patent No. 3565520 covering Palvella’s QTORIN 3.9% rapamycin anhydrous gel formulation and its use in treating microcystic lymphatic malformations and related diseases. The patent provides protection through 2038, per the company disclosure.
Brokerage research has reflected those developments. Clear Street reiterated a Buy rating on Palvella and maintained a $220 price target.
On the outreach front, Palvella launched the BEYOND mLM disease-awareness campaign in partnership with several nonprofit organizations. The campaign is aimed at raising awareness of microcystic lymphatic malformations, a condition the company notes affects more than 30,000 diagnosed patients in the United States who currently lack FDA-approved treatment options.
Market context and company direction
The combination of insider transactions, capital raising, intellectual property protections and advocacy work highlights the company’s simultaneous focus on funding, clinical progress and market positioning. The Form 4 filing documents the specific sale and option exercises by the COO, while corporate disclosures and announcements outline broader strategic moves.
Observers should note that the Form 4 and corporate announcements present discrete facts about insider activity, financing and patent status without attempting to infer causation or future stock performance.